Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.37

Mkt cap

1.8M

Volume

605

High

0.37

P/E Ratio

-0.01

52-wk high

1.11

Low

0.37

Div yield

N/A

52-wk low

0.30

Panbela Therapeutics Inc's shares are trading lower by 26% after the company announced agreements with certain warrant holders to exercise these for 2.13 million shares at a reduced price. This will result in approximately $1.9 million in gross proceeds, excluding financial advisory fees. The reduction in exercise price and issuance of new warrants comply with Nasdaq rules.

Portfolio Pulse from Henry Khederian

November 03, 2023 | 1:55 pm

Panbela Therapeutics has announced the exercise of warrants and the issuance of new warrants in a private placement for $1.9 million in gross proceeds priced at-the-market. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 1:55 pm

Several healthcare stocks experienced significant movement in Friday's pre-market session. Novo Integrated Sciences, Werewolf Therapeutics, Pasithea Therapeutics, Altamira Therapeutics, Arcutis Biotherapeutics, and CVRx saw their stocks rise, with Arcutis Biotherapeutics also releasing its Q3 earnings. On the other hand, Panbela Therapeutics, NexImmune, Agilon Health, Erasca, Turnstone Biologics, and AbCellera Biologics saw their stocks fall, with Agilon Health and AbCellera Biologics also releasing their Q3 earnings.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 1:05 pm

Panbela Therapeutics has exercised warrants and issued new warrants in a private placement, raising $1.9 million in gross proceeds. The transaction was priced at-the-market.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:00 pm

The article lists the stocks that gained and lost the most in Thursday's mid-day session. Some of the top gainers include OmniLit Acquisition Corp., Panbela Therapeutics, Inc., Lemonade, Inc., and Aware, Inc. due to positive news such as merger approvals, publication of clinical data, and strong quarterly results. On the other hand, Outlook Therapeutics, Inc., Confluent, Inc., Remitly Global, Inc., and Acurx Pharmaceuticals, Inc. were among the top losers due to negative news such as additional clinical trials required for approval, mixed financial results, and disappointing efficacy results from a Phase 2 trial.

Portfolio Pulse from Lisa Levin

November 02, 2023 | 6:26 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Virios Therapeutics, Alpine Immune Sciences, Cyclacel Pharmaceuticals, Panbela Therapeutics, Kodiak Sciences, and Omega Therapeutics saw gains, while Outlook Therapeutics, Acurx Pharmaceuticals, Seres Therapeutics, Connect Biopharma Hldgs, DarioHealth, and Kintara Therapeutics experienced losses. Q3 earnings for Seres Therapeutics and DarioHealth were also released.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:31 pm

Panbela Therapeutics Inc's stock is trading higher following the publication of preclinical and clinical data from studies of CPP-1X in recent-onset type 1 diabetes. The data, published in Cell Reports Medicine, showed that CPP-1X may preserve β cell function and is a safe, oral treatment option. The company's shares are up 31.80% at $1.05.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:36 pm

US stocks traded higher with the Dow Jones index gaining more than 250 points and NASDAQ rising 1.22%. Real estate shares jumped by 2.2%. Initial jobless claims increased by 5,000 to 217,000. Panbela Therapeutics, Rocky Brands, and Lemonade saw their shares rise by 44%, 41%, and 36% respectively. Outlook Therapeutics, Confluent, and Remitly Global saw their shares drop by 45%, 44%, and 29% respectively.

Portfolio Pulse from Lisa Levin

November 02, 2023 | 2:13 pm

In Thursday's pre-market session, several healthcare stocks saw significant movement. Panbela Therapeutics, Cellectis, CareDx, Avenue Therapeutics, Genprex, and Akanda saw gains, while Outlook Therapeutics, DarioHealth, Acurx Pharmaceuticals, Moderna, Sonendo, and Envista Holdings experienced losses. Q3 earnings reports for DarioHealth, Moderna, and Envista Holdings were released recently.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 1:06 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the publication of preclinical and clinical data from studies of CPP-1X (DFMO) in recent onset type 1 diabetes (T1D). The data suggests that DFMO treatment may preserve β cell function and health in T1D. The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF. Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.